GlobalData on MSN10h
Relmada acquires Tourette’s therapy rights from Asarina
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.
The Pharma Letter8h
Relmada in-licenses Tourette syndrome drug from Asarina
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...
FierceBiotech7h
After phase 3 miss, Relmada picks up midstage Tourette’s asset from Swedish biotech
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...